Niagen Bioscience (NASDAQ:NAGE) Given New $6.00 Price Target at Freedom Broker

Niagen Bioscience (NASDAQ:NAGE) had its price target lowered by Freedom Broker from $8.50 to $6.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on the stock. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Canaccord Genuity Group cut their target price on Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Friday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.50.

Niagen Bioscience Price Performance

NAGE stock traded down $0.04 during midday trading on Friday, reaching $2.07. The company had a trading volume of 597,674 shares, compared to its average volume of 480,554. Niagen Bioscience has a 1-year low of $2.04 and a 1-year high of $7.28. The stock has a 50 day moving average price of $2.76 and a 200-day moving average price of $3.83. The company has a market capitalization of $164.85 million, a price-to-earnings ratio of 17.25 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The firm had revenue of $27.19 million for the quarter. As a group, research analysts anticipate that Niagen Bioscience will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On Niagen Bioscience

Hedge funds have recently made changes to their positions in the stock. SteelPeak Wealth LLC acquired a new position in Niagen Bioscience during the 1st quarter worth approximately $14,875,000. Arrowstreet Capital Limited Partnership lifted its stake in Niagen Bioscience by 47.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after purchasing an additional 761,685 shares during the last quarter. Tieton Capital Management LLC acquired a new stake in Niagen Bioscience in the second quarter valued at approximately $6,407,000. Sei Investments Co. boosted its position in Niagen Bioscience by 155.6% in the first quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock valued at $4,285,000 after buying an additional 591,495 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Niagen Bioscience by 45.4% during the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after buying an additional 414,725 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Niagen Bioscience News Summary

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
• Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.